Answers are grounded in this paper and cite their sources.
Two preclinical studies show that boosting numbers of T cells or rendering T cells resistant to the immunosuppressant tacrolimus are potential approaches for the treatment of post-transplantation lymphoproliferative disease associated with EBV infection.
No takes yet. Share an insight, caveat, or question.
Dharnidharka et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: